Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
A Phase I trial of the small non-peptide GLP-1 receptor agonist danuglipron in 98 patients with type 2 diabetes found that it had a similar glucose-lowering ability as the clinically used GLP-1 receptor agonists and was well tolerated during the 4 week study period [43]
K., Streu, C
Greater adherence was associated with greater improvements in HbA1c levels for both treatment regimens
It is typically found in the brain and easily passes the blood-brain barrier
US$ 26.59
US$ 21.00
US$ 26.74
US$ 20.16
US$ 26.13
US$ 24.64
US$ 27.36
